Mayne Pharma Group (ASX:MYX) said it forecasts growth in its revenue for the fiscal first half ended Dec. 31, 2024, according to a Monday Australian bourse filing.

The firm now expects H1 revenue to be AU$210 million to AU$215 million, reflecting a 12% to 14% rise in the same half-year period the previous year, the filing said.

It also expects to report underlying earnings before interest, taxes, depreciation, and amortization during the period of AU$30 million to AU$32 million, representing an increase of 275% to 300% on the prior year period, driven by continued growth across the women's health portfolio, the filing said.

Its cash and marketable securities came in at AU$124.9 million as of Dec. 31, 2024, a decline of AU$4.6 million compared to the balance as of Oct. 31, 2024.

The firm's shares rose past 16% in early trading on Monday.